Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2021 - 07 - 06 save search
NextCure Initiates Phase 1/2 Clinical Trial of NC762 for Solid Tumors
Published: 2021-07-06 (Crawled : 21:00) - globenewswire.com
NXTC | $1.67 6.37% 5.99% 62K
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.65%
solid tumors phase 1 trial phase 2 phase 3
FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients
Published: 2021-07-06 (Crawled : 19:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: -1.05%
H: 1.06%
C: -12.02%
treatment fda phase 2 opioid osteoarthritis trial fda clearance
Worldwide Industrial Automation Industry to 2027 - Growing Number of SMEs Presents Opportunities
Published: 2021-07-06 (Crawled : 18:00) - prnewswire.com
ROK | News | $269.96 -1.29% 0.0% 1.2M
|
Producer Manufacturing
|
| O: 0.42%
H: 0.08%
C: -0.85%
GE | $148.06 -3.19% 0.0% 9.5M
|
Electronic Technology
|
| O: -1.78%
H: 0.3%
C: -2.71%
growing trial
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global Clinical Program Update
Published: 2021-07-06 (Crawled : 17:00) - biospace.com/
ASND | $140.19 -0.5% -0.5% 270K
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: -1.57%
phase 3 trial enroll
NRx Pharmaceuticals Announces Initiation of Emergency Use Training and Extension of Phase 2/3 Inhaled ZYESAMI™ (Aviptadil-acetate) Trial in the Nation of Georgia
Published: 2021-07-06 (Crawled : 14:00) - biospace.com/
NRXP 1 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.42%
H: 2.17%
C: -8.42%
phase 2 phase 2/3 trial merge aviptadil train
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
Published: 2021-07-06 (Crawled : 14:00) - globenewswire.com
ADIL | $1.9 -12.44% -14.21% 310K
|
Health Technology
|
| O: 7.76%
H: 1.17%
C: -2.93%
phase 3 trial enroll
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease
Published: 2021-07-06 (Crawled : 12:00) - athira.com
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 1.15%
H: 5.59%
C: 4.17%
disease alzheimer clinical trials trial ath-1017 alzheimer’s alzheimer's disease alzheimer's
EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
EYPT | $17.665 0.94% 0.93% 1.5M
|
Health Technology
|
| O: 1.7%
H: 0.78%
C: -7.03%
eye positive results trial dmd
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ABUS | News | $2.725 -0.18% -0.18% 930K
|
Health Technology
|
| O: -3.87%
H: 0.0%
C: -1.68%
hepatitis biopharma collaboration trial injection infections chronic hepatitis b
Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s DiseaseStudy Extension allows for additional 26 weeks of treatment on ATH-1017
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ATHA | $2.12 2.91% 2.83% 200K
|
Health Technology
|
| O: 1.15%
H: 5.59%
C: 4.17%
disease alzheimer treatment clinical trials trial ath-1017 alzheimer’s alzheimer's
CytoSorbents Receives Full FDA Approval of Investigational Device Exemption (IDE) for U.S. STAR-T Trial on Ticagrelor Removal During Cardiothoracic Surgery
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
CTSO | $0.8026 0.2% 0.2% 46K
|
Health Technology
|
| O: 2.07%
H: 12.34%
C: 10.67%
fda fda approval device iot cardio trial approval
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2021-07-06 (Crawled : 12:00) - biospace.com/
ISEE | $39.95 0.38% 0.38% 0
|
Health Technology
|
| O: 18.57%
H: 12.89%
C: 3.49%
fda phase 3 trial macular
Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Published: 2021-07-06 (Crawled : 11:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.69%
H: 0.83%
C: 0.77%
heart results trial
Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia
Published: 2021-07-06 (Crawled : 06:00) - globenewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: 1.54%
H: 0.03%
C: -0.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.0%
H: 0.1%
C: -0.25%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: -3.41%
H: 2.32%
C: -0.59%
covid phase 2 trial covid-19
COVID-19 Impact and Analysis|Artificial Intelligence Market In The Industrial Sector| Technavio
Published: 2021-07-06 (Crawled : 03:00) - prnewswire.com
SAP | News | $175.77 -1.61% 0.0% 950K
|
Technology Services
|
| O: 1.14%
H: 0.32%
C: -0.59%
GOOGL | News S | $154.08 -1.24% -1.25% 32M
|
Technology Services
|
| O: 2.06%
H: 0.62%
C: 0.43%
GOOG | News S | $155.7 -1.12% -1.13% 20M
|
Technology Services
|
| O: 2.05%
H: 0.34%
C: 0.25%
covid artificial intelligence ce mark trial covid-19
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF)
Published: 2021-07-06 (Crawled : 00:00) - prnewswire.com
KPTI | $1.16 -9.38% -10.34% 1.4M
|
Health Technology
|
| O: -0.93%
H: 0.28%
C: -4.62%
treatment fibrosis china trial
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
Published: 2021-07-05 (Crawled : 00:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -9.85%
H: 0.79%
C: 0.45%
solid tumors china trial erk
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.